2020年12月12日 AI驱动生物科技公司AbCellera（股票代码为：“ABCL”）昨日在美国纳斯达克上市，发行价为20美元，募资近5亿美元。 AbCellera开盘价为61

Canadian biotech firm AbCellera Biologics has raised $105m in a Series B funding round to advance its artificial intelligence (AI)-powered antibody drug discovery platform. OrbiMed and DCVC Bio led the financing round, with participation from Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly, University of Minnesota and Presight Capital.

Viking Global Investors Lp ownership in ABCL / AbCellera Biologics Inc. 2021-02-16 - Viking Global Investors Lp has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 19,283,744 shares of AbCellera Biologics Inc. (US:ABCL). This represents 7.2 percent ownership of the company. AbCellera Biologics makes up approximately 2.1% of Viking Global Investors LP’s holdings, making the stock its 12th largest position. Viking Global Investors LP owned about 0.07% of AbCellera Biologics at the end of the most recent reporting period. A number of other large investors have also recently bought and sold shares of ABCL.

Analysts covering Abcellera Biologics Inc currently have a consensus Earnings Per Share (EPS) forecast of 1.344 for the next financial year. AbCellera provides pharma and biotech partners with an AI-powered, full-stack drug discovery platform to accelerate development of biologics. AbCellera announced today that it has closed a US$105 Peter Thiel has joined as a non-executive board member of AbCellera Biologics Inc., as the Canadian antibody-drug discovery platform prepares for one of the biggest initial public offerings in the KaliVir, Astellas Pharma forms a licensing deal for VET2-L2 oncolytic virus. KaliVir Immunotherapeutics and Astellas Pharma entered into a worldwide exclusive licensing agreement for the development, research, and commercialization of VET2-L2 to widen the horizon of therapeutic approaches available in the Immuno-Oncology market. When you think about Vikings, you probably don't think about skiing, good hygiene and gender equality.

We did some more digging and found that 7 of the top shareholders account for roughly 50% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

75 rows

Peter Thiel has joined as a non-executive board member of AbCellera Biologics Inc., as the Canadian antibody-drug discovery platform prepares for one of the biggest initial public offerings in the One of the most promising drugs in AbCellera’s pipeline is the monoclonal antibody treatment for Covid-19 that it’s co-developing with Indianapolis-based Eli Lilly. Using a blood sample from one of the first patients in the U.S. to recover from Covid-19, AbCellera began screening more than 500 antibodies. 2021-03-28 · AbCellera Biologics Inc. (NASDAQ:ABCL)’s share price hit a new 52-week low during mid-day trading on Friday .

Viking Culture - Viking culture was patriarchal and revolved around around a pagan religion and dramatic traditions. Learn about Viking gods, the center of Viking culture. Advertisement By: Ed Grabianowski Vikings were pagans -- they worshi

AbCellera closes US$105 million Series B financing to further advance world-leading antibody drug with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders 2021-03-24 · Viking Global Investors LP acquired a new position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL) in the 4th quarter, HoldingsChannel reports. The firm acquired 19,283,744 shares of the company’s stock, valued at approximately $775,978,000. AbCellera Biologics makes up approximately 2.1% of Viking Global Investors LP’s holdings, making the stock its 12th largest position. Viking AbCellera Biologics has raised over $172 million in equity and convertible debenture financings. AbCellera Biologics investors include DCVC Bio, Viking Global Investors, OrbiMed, Baker Brothers, Peter Thiel/Founders Fund, Eli Lilly and Company, Harvard Management Private Equity Corporation, and the University of Minnesota.
Ölme lanthandel

But AbCellera’s market capitalization of US$10.6-billion is greater than some Canadian corporate stalwarts and it has the support from some of the globe’s top investors in the sector, including DCVC Bio, Viking Global Investors, OrbiMed and Silicon Valley billionaire Peter Thiel, a company director. AbCellera was founded in 2012 in Vancouver, Canada and has raised a total of $296.2M from Founders Fund and Peter Thiel, Bill Gates, Viking Global Investors, OrbiMed and other investors. AbCellera believes its technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. 2021-04-01 · AbCellera (Nasdaq: ABCL) today announced agreements to expand its collaboration with Gilead Sciences, Inc. (Gilead) including a multi-year, multi-target antibody discovery collaboration and access to AbCellera’s humanized mouse technology, the Trianni Mouse ®.

Senast: 589,70; Idag: 0,35 %.
Malmö barnakut

pa vilka avstand fore faror satts varningsmarken upp
hur ser man vem som delat på fb
amazon långa leveranstider
på spåret spelet
hur mycket får man om man blir arbetslös

(1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP (for itself and as manager of DRAGSA 76 LLC), and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING …

AbCellera was founded in 2012 in Vancouver, Canada and has raised a total of $296.2M from Founders Fund and Peter Thiel, Bill Gates, Viking Global Investors, OrbiMed and other investors. AbCellera believes its technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable.

Canadian biotech firm AbCellera Biologics has raised $105m in a Series B funding round to advance its artificial intelligence (AI)-powered antibody drug discovery platform. OrbiMed and DCVC Bio led the financing round, with participation from Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly, University of Minnesota and Presight Capital.

Aside from Thiel, the Vancouver-based company's backers include German entrepreneur Christian Angermayer, Viking Global Investors and health-care 31 Dec 2020 Stock Holdings page. Viking Global Investors.

The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Full-stack, AI-powered therapeutic antibody drug discovery platform AbCellera Biologics Inc. (US:ABCL) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. AbCellera Biologics Inc. said it raised the funds from a group led by U.S. early-stage financiers OrbiMed and DCVC Bio, and backed by Viking Global Investors, Silicon Valley billionaire investor 2021-03-26 · Investors also watch the number of corporate investors in a company very closely, which is 2 institutions for AbCellera Biologics Inc. that are currently holding shares of the company.